Pediatric neuroendocrine tumors (NETs) and neuroblastomas are rare malignancies with poor outcomes when metastatic. Limited treatment options are currently available for pediatric NETs. Recently, radioligand therapy (RLT) consisting of a radionuclide attached to a ligand, such as [177Lu]Lu-DOTA-TATE, has been approved for the treatment of NETs in adolescents aged ≥12 years. Although long-term safety of RLT in adolescents and other pediatric patients needs to be further investigated, data from large adult studies and early pediatric studies suggest feasibility and low toxicity. Future research is needed to assess potential combinations of RLTs with conventional chemotherapy and radiation sensitizers in order to optimize the treatment for pediatric patients with NETs. This review highlights the current status and future directions for RLTs as theranostics for pediatric patients with NETs and neuroblastomas.
儿童神经内分泌肿瘤和神经母细胞瘤是罕见的恶性肿瘤，一旦发生转移预后较差。目前针对儿童神经内分泌肿瘤的治疗选择有限。近年来，放射性配体疗法（由放射性核素与配体结合而成，如[¹⁷⁷Lu]Lu-DOTA-TATE）已获准用于治疗12岁及以上青少年神经内分泌肿瘤。尽管该疗法在青少年及其他儿童患者中的长期安全性仍需进一步研究，但来自大规模成人研究及早期儿科研究的数据表明其具有可行性和低毒性特征。未来需开展研究评估放射性配体疗法与传统化疗及放射增敏剂的联合应用潜力，以优化儿童神经内分泌肿瘤患者的治疗方案。本综述重点阐述放射性配体疗法作为儿童神经内分泌肿瘤和神经母细胞瘤诊疗一体化手段的现状与未来发展方向。
Treating Pediatric Oncology Patients: The Emerging Role of Radioligand Therapy
肿瘤(癌症)患者之家